Policlinico Gemelli and Palantir Technologies Partner to Use AI to Advance Data Science for Healthcare
8.9.2023 13:59:00 EEST | Business Wire | Press release
Palantir Technologies Inc. (NYSE: PLTR) (“Palantir”) and Gemelli Generator Real World Data (RWD), a research facility of Fondazione Policlinico Universitario A. Gemelli IRCCS (“Policlinico Gemelli”), today announced a partnership to implement digital medicine research solutions that leverage artificial intelligence to improve patient care and health outcomes.
Policlinico Gemelli’s digital research center, Generator RWD, will utilize Palantir Foundry as one of the key enabling platforms to manage the full scale and complexity of healthcare data. Foundry’s AI capabilities will be utilized to generate Real World Evidence in support of clinical and translational research aimed at drug and indication discovery, improved patient care, and the development of digital medicine solutions for healthcare research in Italy and within their partnerships at global scale.
Palantir’s software will boost the capabilities of Generator RWD and its partner network as they continue in their quest to strengthen the exploitation of data to gain new insights in several healthcare research domains.
“Healthcare is transforming through the power of data and AI, and this trend will only accelerate. More and more of the industry is wielding this power to discover novel therapies, improve patient care and increase treatment efficiency and effectiveness,” said Andrea Galvagni, Head of Italy at Palantir. “At Palantir, we are proud to support world-leading institutions such as Policlinico Gemelli by providing them with the technology they need to achieve their most critical missions.”
"Real World Evidence is constantly gaining traction in support of research in healthcare. By integrating Foundry in the framework developed at Generator RWE, we aim at accelerating our research pipeline cycles to deliver faster and better outcomes,” said Vincenzo Valentini, Scientific Director of Gemelli Generator Research Facility.
"The added value of Palantir software and their deep skills in data-driven innovation will enrich the suite of products and services we are delivering within co-creation projects with our industrial partners," said Alfredo Cesario, CEO of Gemelli Digital Medicine & Health.
About Palantir Technologies Inc.
Foundational software of tomorrow. Delivered today. Additional information is available at https://www.palantir.com.
About Policlinico Gemelli
Gemelli Generator is an innovative center with multidisciplinary skills, which originates from the awareness of the need for tools capable to collect, store and analyze the huge amount of data generated every day from heterogeneous sources, translating them into understandable and usable information while fully respecting the privacy, data integrity and intellectual property, for the benefit of all.
Gemelli Generator, built in collaboration with the Università Cattolica del Sacro Cuore, is one of the projects of the Gemelli Science and Technological Park (GSTeP) of the Fondazione Policlinico Universitario A. Gemelli IRCCS, with the aim to provide physicians and researchers with a wide ranging research facility.
To support diagnosis and treatment and clinical processes, Gemelli Generator offers Artificial Intelligence and Big Data processing services for the integration of clinical data and the development of predictive models; aiming at the clinical and scientific valorisation of the skills, processes and data of the Data Warehouse (DWH) of the Fondazione Policlinico Universitario A. Gemelli IRCCS, through advanced data extraction, collection and analysis services.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements may relate to, but are not limited to, Palantir’s expectations regarding the amount and the terms of the contract and the expected benefits of our software platforms. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Forward-looking statements are based on information available at the time those statements are made and were based on current expectations as well as the beliefs and assumptions of management as of that time with respect to future events. These statements are subject to risks and uncertainties, many of which involve factors or circumstances that are beyond our control. These risks and uncertainties include our ability to meet the unique needs of our customer; the failure of our platforms to satisfy our customer or perform as desired; the frequency or severity of any software and implementation errors; our platforms’ reliability; and our customer’s ability to modify or terminate the contract. Additional information regarding these and other risks and uncertainties is included in the filings we make with the Securities and Exchange Commission from time to time. Except as required by law, we do not undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments, or otherwise.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230908825834/en/
Contact information
Media Contacts
Palantir
Lisa Gordon
media@palantir.com
Policlinico Gemelli
Nicola Cerbino
nicola.cerbino@policlinicogemelli.it
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
UPS Announces Agreement to Acquire Smartways Logistics17.11.2026 23:00:00 EET | Press release
UPS (NYSE: UPS) today announced it has entered into an agreement to acquire Smartways Logistics (Smartways), a healthcare logistics provider serving Australia and New Zealand. Once completed, the acquisition will enhance UPS Healthcare’s time-critical transportation capabilities in the region. Smartways enables healthcare customers to move critical shipments quickly and reliably, with specialized services for life sciences, medical devices, clinical trials and radiopharmaceuticals. The acquisition will build on UPS Healthcare’s ability to deliver for customers with urgent and complex logistics needs, while expanding the services available in Australia, New Zealand and the Asia Pacific region. “As healthcare becomes increasingly complex, logistics plays an even more critical role. It takes specialized capabilities and precision at every step to help vital healthcare products reach patients safely, reliably and when they’re needed,” said Wilfredo Ramos, UPS EVP and Chief International, H
Spatial Announces Release 2027 1.0 with New Enhancements Across CAD Modeling, Interoperability, Data Preparation, and Meshing17.11.2026 21:10:00 EET | Press release
Spatial Corp., the leading software development kit provider for design, manufacturing and engineering solutions and a subsidiary of Dassault Systèmes, today announced the availability of its 2027 1.0 Release. This latest release introduces new capabilities and enhancements across Spatial's 3D ACIS Modeler, CGM Modeler, 3D InterOp, Data Prep and CSM/CVM product lines. Designed to improve efficiency, flexibility and robustness across CAD modeling, interoperability, data preparation and simulation workflows, the release delivers enhanced geometry processing, expanded modeling capabilities, improved CAD translation and advances in mesh generation for a better workflow coverage. 3D ACIS Modeler Enhanced Blending (Filleting) The 3D ACIS Modeler introduces support for asymmetric fixed-width blends with a conic cross-section, providing users with finer control over smooth transitions between edges. This enhancement builds on the symmetric fixed-width blend with a conic cross-section capabilit
Global EV Alliance Survey: EV Drivers Identify Myths and Misconceptions as the Biggest Barrier to Adoption17.11.2026 20:00:00 EET | Press release
Myths and misconceptions about electric cars, from battery lifespan and fire risk to grid collapse, are the biggest barrier to EV adoption, according to respondents to the annual Global EV Driver Survey. The 2026 survey draws on responses from more than 29,500 EV drivers across 34 countries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261117539716/en/ MYTHS. Battery lifespan (72%), fire risk (58%) and grid collapse (45%) top the list of EV myths reported by respondents to the 2026 Global EV Driver Survey, which gathered responses from more than 29,500 EV drivers across 34 countries. “The EV transition is not just an infrastructure or affordability challenge. It is also an information challenge. Outdated information and misconceptions continue to influence decisions long after the technology has moved on,” says Ellen Hiep, from the Steering Committee of the Global EV Alliance (GEVA). Myths the greatest barrier Asked to ide
KILL Trulioo’s Global Risk Platform Unlocks Device and Behavioral Intelligence Via Bureau Partnership17.11.2026 20:00:00 EET | Press release
Trulioo requests that their press release NewsItemId: 20261117163539 “Trulioo’s Global Risk Platform Unlocks Device and Behavioral Intelligence Via Bureau Partnership” be killed. The release was issued in error by Trulioo.
TreeFrog Therapeutics Appoints James Sterling as Chief Financial Officer17.11.2026 19:04:00 EET | Press release
TreeFrog Therapeutics, a biotechnology company developing scalable cell therapies built on its proprietary C-Stem™ technology, today announced the appointment of James Sterling as Chief Financial Officer, effective November 1, 2026. James joins TreeFrog’s executive leadership team and reports to Mark Rothera, President and Chief Executive Officer. He oversees finance, investor relations and corporate development as the company enters its next phase of growth. “I am delighted to welcome James to TreeFrog. James brings a valuable combination of biotech CFO and Wall Street experience that supports our ambitions to develop TreeFrog into a key enabling partner and drug developer in the regenerative medicines field,” said Mark Rothera, President and Chief Executive Officer of TreeFrog Therapeutics. James contributes deep experience in corporate finance, capital markets and strategic planning across therapeutics and diagnostics. Recently, he served as Chief Financial Officer of Bluebird Bio (
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
